# US 2003/0216419 A1 · Isomeric fused pyrrolocarbazoles and isoindolones

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0216419 A1
- Document ID: US20030216419A1
- Status: Published application
- Kind: A1
- Application number: 10/422,164
- Filed: 2003-04-24
- Published: 2003-11-20
- Earliest claimed: 1999-08-20
- Assignees: Cephalon, Inc.
- Inventors: Robert L. Hudkins
- Web page: https://patentgrep.com/patent/US20030216419A1

## CPC

- C07D 471/14: Ortho-condensed systems
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/08: of the prostate
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 487/04: Ortho-condensed systems
- C07D 491/14: Ortho-condensed systems
- C07D 495/14: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is directed to novel fused pyrrolocarbazoles and isoindolones, including pharmaceutical compositions, diagnostic kits, assay standards or reagents containing the same, and methods of using the same as therapeutics. The invention is also directed to intermediates and processes for making these novel compounds.

## Claims

### Claim 1

A compound of Formula I:
30
or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein:
ring D is selected from phenyl and cyclohexene with double bond a-b;
ring B and ring F, independently, and each together with the carbon atoms to which they are attached, are selected from:
a) a 6-membered carbocyclic ring in which from 1 to 3 carbon atoms may be replaced by hetero atoms; and
b) a 5-membered carbocyclic ring in which either
1) one carbon atom may be replaced with an oxygen, nitrogen, or sulfur atom;
2) two carbon atoms may be replaced with a sulfur and a nitrogen atom, an oxygen and a nitrogen atom, or two nitrogen atoms; or
3) three carbon atoms may be replaced with three nitrogen atoms, one oxygen and two nitrogen atoms, or one sulfur and two nitrogen atoms;
G—X—W is selected from:
a) —(A1A2)C—N(R1)—C(B1B2)—;
b) —CH(R1A)—C(═O)—N(R1)—; and
c) —N(R1)—C(═O)—CH(R1A)—;
R1 is selected from:
a) H, substituted or unsubstituted alkyl of 1 to 6 carbons, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heteroarylalkyl;
b) —C(═O)R7, where R7 is selected from substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted carbocyclic group, and substituted or unsubstituted heterocyclyl groups;
c) —OR8 , where R8 is selected from H and alkyl having from 1 to 6 carbons;
d) —C(═O)NHR8, —NR9R10, —(CH2)pNR9R10, —(CH2)pOR8, —O(CH2)pOR8 and —O(CH2)pNR9R10, where p is from 1 to 4; and where either
1) R9 and R10 are each independently selected from H, unsubstituted alkyl of 1 to 6 carbons, and substituted alkyl; or
2) R9 and R10 together form a linking group of the formula —(CH2)2—X1—(CH2)2—, wherein X1 is selected from —O—, —S—, and —CH2—;
R1A is the same as R1;
R2, R3, R4 and R5 are each independently selected from:
a) H, aryl, carbocyclyl, heterocyclyl, —CN, CF3, —NO2, —OH, —OR7, Br, I, —O(CH2)pNR9R10, —OC(═O)R7, —OC(═O)NR9R10, —O(CH2)pOR8, F, Cl —CH2OR8, —NR9R10, —NR8S(═O)2R7, —NR8C(═O)R7, or —NR8C(═S)R7;
b) —CH2OR11, where R11 is the residue of an amino acid after the hydroxyl group of the carboxyl group is removed;
c) —NR8C(═O)NR9R10, —NR8C(═S)NR9R10, —CO2R12, —C(═O)R12, —C(═O)NR9R10, —C(═S)NR9R10, —CH═NOR12, —CH═NR7, —(CH2)pNR9R10, —(CH2)pNHR11, or —CH═NNR12R12A; where R12 is selected from H, alkyl of 1 to 6 carbons, —OH, alkoxy of 1 to 6 carbons, —OC(═O)R7, —OC(═O)NR9R10, —OC(═S)NR9R10, —O(CH2)pNR9R10, —O(CH2)pOR8, substituted or unsubstituted arylalkyl having from 6 to 10 carbons, substituted or unsubstituted heterocyclylalkyl, and a substituted or unsubstituted carbocyclic group; R12A is the same as R12;
d) —S(O)yR12, —(CH2)pS(O)yR7, —CH2S(O)yR11 where y is 0, 1 or 2;
e) alkyl of 1 to 8 carbons, alkenyl of 2 to 8 carbons, and alkynyl of 2 to 8 carbons, wherein:
1) each alkyl, alkenyl, or alkynyl group is unsubstituted; or
2) each alkyl, alkenyl or alkynyl group is substituted with 1 to 3 groups selected from aryl of 6 to 10 carbons, heterocyclyl, arylalkoxy, heterocycloalkoxy, hydroxylalkoxy, alkyloxy-alkoxy, hydroxyalkylthio, alkoxy-alkylthio, F, Cl, Br, I, —CN, —NO2, —OH, —OR7, —X2(CH2)pC(═O)NR9R10, —X2(CH2)pC(═S)NR9R10, —X2(CH2)pOC(═O)NR9R10, —X2(CH2)pCO2R7, —X2(CH2)pS(O)yR7,—X2(CH2)pNR8C(═O)NR9R10, —OC(═O)R7, —OC(═O)NHR12, O-tetrahydropyranyl, —NR9R10, —NR8CO2R7,—NR8C(═O)NR9R10, —NR8C(═S)NR9R10, —NHC(═NH)NH2, —NR8C(═O)R7, —NR8C(═S)R7, —NR8S(═O)2R7, —S(O)yR7, —CO2R12, —C(═O)NR9R10, —C(═S)NR9R10, —C(═O)R12, —CH2OR8, —CH═NNR12R12A, —CH═NOR12, —CH═NR7, —CH═NNHCH(N═NH)NH2, —S(═O)2NR12R12A, —P(═O)(OR8)2, —OR11, and a monosaccharide of 5 to 7 carbons where each hydroxyl group of the monosaccharide is independently either unsubstituted or is replaced by H, alkyl of 1 to 4 carbons, alkylcarbonyloxy of 2 to 5 carbons, or alkoxy of 1 to 4 carbons;
X2is O, S, or NR8;
Q is selected from —NR6, —O—, and —S—;
R6is selected from H, —SO2R7, —CO2R7, —C(═O)R7, —C(═O)NR9R10, alkyl of 1-8 carbons, alkenyl of 2-8 carbons, and alkynyl of 2-8 carbons; and either
1) each alkyl, alkenyl, or alkynyl group is unsubstituted; or
2) each alkyl, alkenyl, or alkynyl group independently is substituted, as defined for R2, R3, R4, and R5 in e) above;
Y is selected from:
a) an unsubstituted alkylene of 1-3 carbons;
b) an alkylene of 1-3 carbons substituted with R13, where R13 is selected from R12, thioalkyl of 1-4 carbons, halogen, alkyl of 1-8 carbons, alkenyl of 2-8 carbons, and alkynyl of 2-8 carbons, where
i) each alkyl of 1-8 carbons, alkenyl of 2-8 carbons, and alkynyl of 2-8 carbons is unsubstituted; or
ii) each alkyl of 1-8 carbons, alkenyl of 2-8 carbons, and alkynyl of 2-8 carbons, independently, is substituted, as defined for R2, R3, R4, and R5 in e) above; and
c) a functional group selected from —CH═CH—, —CH(OH)—CH(OH)—, —O—, —S—, —S(═O)—, —S(═O)2—, —C(R6)2—, —C═C(R13)2—, —C(═O)—, —C(═NOR12)—, —C(OR12)R12—, —C(═O)CH(R6)—, —CH(R6)C(═O)—, —C(═NOR12)CH(R6)—, —CHR8C(═NOR12)—, —C(═O)N(R8)—, —N(R8)C(═O)—, —CH2Z—, —ZCH2—, and —CH2ZCH2—, where Z is selected from —C(R12)—, —O—, —S—, —CO2R12, —C(═NOR12)—, and —N(R12)—;
A1 and A2 are selected from H, H; H, OR12; H, —SR12; H, —N(R12)2; and a group where A1 and A2 together form a moiety selected from ═O, ═S, and ═NR12; and,
B1 and B2 are selected from H, H; H, —OR12; H, —SR12; H, —N(R12)2; and a group where B1 and B2 together form a moiety selected from ═O, ═S, and ═NR12;
with the proviso that at least one of the pairs A1 and A2, or B1 and B2, form ═O.

### Claim 2

A compound of Formula XXII:
31
or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein:
ring D is selected from phenyl and cyclohexene with double bond a-b;
ring B and ring F, independently, and each together with the carbon atoms to which they are attached, are selected from:
a) a 6-membered carbocyclic ring in which from 1 to 3 carbon atoms may be replaced by hetero atoms; and
b) a 5-membered carbocyclic ring in which either
1) one carbon atom may be replaced with an oxygen, nitrogen, or sulfur atom;
2) two carbon atoms may be replaced with a sulfur and a nitrogen atom, an oxygen and a nitrogen atom, or two nitrogen atoms; or
3) three carbon atoms may be replaced with three nitrogen atoms, one oxygen and two nitrogen atoms, or one sulfur and two nitrogen atoms;
G—X—W is selected from:
a) —(A1A2)C—N(R1)—C(B1B2)—;
b) —CH(R1A)—C(═O)—N(R1)—; and
c) —N(R1)—C(═O)—CH(R1A)—;
R1 is selected from:
a) H, substituted or unsubstituted alkyl of 1 to 6 carbons, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heteroarylalkyl;
b) —C(═O)R7, where R7 is selected from substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbocyclic group, and substituted or unsubstituted heterocyclyl groups;
c) —OR8, where R8 is selected from H and alkyl having from 1 to 6 carbons;
d) —C(═O)NHR8, —NR9R10, —CH2)pNR9R10, —(CH2)pOR8, —O(CH2)pOR8 and —O(CH2)pNR9R10, where p is from 1 to 4; and where either
1) R9 and R10 are each independently selected from H, unsubstituted alkyl of 1 to 6 carbons, and substituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl; or
2) R9 and R10 together form a linking group of the formula —(CH2)2—X1—(CH2)2—, wherein X1 is selected from —O—, —S—, and —CH2—;
R1A is the same as R1;
R2, R3, R4 and R5 are each independently selected from:
a) H, aryl, carbocyclyl, heterocyclyl, —CN, CF3, —NO2, —OH —OR7, Br, I, —O(CH2)pNR9R10, —OC(═O)R7, —OC(═O)NR9R10, —O(CH2)pOR8, F, Cl, —CH2OR8, —NR9R10, —NR8S(═O)2R7, —NR8C(═O)R7, or —NR8C(═S)R7;
b) —CH2OR11, where R11 is the residue of an amino acid after the hydroxyl group of the carboxyl group is removed;
c) —NR8C(═O)NR9R10, —NR8C(═S)NR9R10, —CO2R12, —C(═O)R12, —C(═O)NR9R10, —C(═S)NR9R10, —CH═NOR12, —CH═NR7, —(CH2)pNR9R10, —(CH2)pNHR11, or —CH═NNR12R12A; where R12 is selected from H, alkyl of 1 to 6 carbons, —OH, alkoxy of 1 to 6 carbons, —OC(═O)R7, —OC(═O)NR9R10, —OC(═S)NR9R10, —O(CH2)pNR9R10, —O(CH2)pOR8, substituted or unsubstituted arylalkyl having from 6 to 10 carbons, substituted or unsubstituted heterocyclylalkyl, and a substituted or unsubstituted carbocyclic group; R12A is the same as R12;
d) —S(O)yR12, —(CH2)pS(O)yR7, —CH2S(O)yR11 where y is 0, 1 or 2;
e) alkyl of 1 to 8 carbons, alkenyl of 2 to 8 carbons, and alkynyl of 2 to 8 carbons, wherein:
1) each alkyl, alkenyl, or alkynyl group is unsubstituted; or
2) each alkyl, alkenyl or alkynyl group is substituted with 1 to 3 groups selected from aryl of 6 to 10 carbons, heterocyclyl, arylalkoxy, heterocycloalkoxy, hydroxylalkoxy, alkyloxy-alkoxy, hydroxyalkylthio, alkoxy-alkylthio, F, Cl, Br, I, —CN, —NO2, —OH, —OR7, —X2(CH2)pC(═O)NR9R10, —X2(CH2)pC(═S)NR9R10, —X2(CH2)pOC(═O)NR9R10, —X2(CH2)pCO2R7, —X2(CH2)pS(O)yR7,—X2(CH2)pNR8C(═O)NR9R10, —OC(═O)R7, —OC(═O)NHR12, O-tetrahydropyranyl, —NR9R10, —NR8CO2R7, —NR8C(═O)NR9R10, —NR8C(═S)NR9R10, —NHC(═NH)NH2, —NR8C(═O)R7, —NR8C(═S)R7, —NR8S(═O)2R7, —S(O)yR7, —CO2R12, —C(═O)NR9R10, —C(═S)NR9R10, —C(═O)R12, —CH2OR8, —CH═NNR12R12A, —CH═NOR12, —CH═NR7, —CH═NNHCH(N═NH)NH2, —S(═O)2NR12R12A, —P(═O)(OR8)2, —OR11, and a monosaccharide of 5 to 7 carbons where each hydroxyl group of the monosaccharide is independently either unsubstituted or is replaced by H, alkyl of 1 to 4 carbons, alkylcarbonyloxy of 2 to 5 carbons, or alkoxy of 1 to 4 carbons;
X2 is O, S, or NR8;
Q is selected from —NR6, —O—, and —S—;
R6 is selected from H, —SO2R7, —CO2R7, —C(═O)R7, —C(═O)NR9R10, alkyl of 1-8 carbons, alkenyl of 2-8 carbons, and alkynyl of 2-8 carbons; and either
1) each alkyl, alkenyl, or alkynyl group is unsubstituted; or
2) each alkyl, alkenyl, or alkynyl group independently is substituted, as defined for R2, R3, R4, and R5 in e) above;
Y is selected from:
a) an unsubstituted alkylene of 1-3 carbons;
b) an alkylene of 1-3 carbons substituted with R13, where R13 is selected from R12, thioalkyl of 1-4 carbons, halogen, alkyl of 1-8 carbons, alkenyl of 2-8 carbons, and alkynyl of 2-8 carbons, where
i) each alkyl of 1-8 carbons, alkenyl of 2-8 carbons, and alkynyl of 2-8 carbons is unsubstituted; or
ii) each alkyl of 1-8 carbons, alkenyl of 2-8 carbons, and alkynyl of 2-8 carbons, independently, is substituted, as defined for R2, R3, R4, and R5 in e) above; and
c) a functional group selected from —CH═CH—, —CH(OH)—CH(OH)—, —O—, —S—, —S(═O)—, —S(═O)—, —C(R6)2—, —C═C(R13)2—, —C(═O)—, —C═N(R13)—, —C(═NOR12)—, —C(OR12)R12—, —C(═O)CH(R6)—, —CH(R6)C(═O)—, —C(═NOR12)CH(R6)—, —CHR8C(═NOR12)—, —C(═O)N(R8)—, —N(R8)C(═O)—, —CH2Z—, —ZCH2—, and —CH2ZCH2, where Z is selected from —C(R2)—, —O—, —S—, —CO2R12, —C(═NOR12)—, and —N(R12)—;
A1 and A2 are selected from H, H; H, OR12; H —SR12; H, —N(R12)2; and a group where A1 and A2 together form a moiety selected from ═O, ═S, and ═NR12; and,
B1 and B2 are selected from H, H; H, —OR12; H, —SR12; H, —N(R12)2; and a group where B1 and B2 together form a moiety selected from ═O, ═S, and ═NR12;
with the proviso that at least one of the pairs A1 and A2, or B1 and B2, form ═O.

### Claim 3 (depends on 1)

The compound of claim 1 wherein R1, R3, and R5 are H.

### Claim 4 (depends on 3)

The compound of claim 3 wherein -G-X—Y— is —CH2N(R1)C(═O)—, —C(═O)N(R1)CH2—, or —C(═O)N(R1)C(═O)—.

### Claim 5 (depends on 1)

The compound of claim 1 wherein rings B and F are independently substituted or unsubstituted phenyl or pyridyl.

### Claim 6 (depends on 1)

The compound of claim 1 wherein Q is —NR6, and R6 is H or substituted or unsubstituted lower alkyl.

### Claim 7 (depends on 1)

The compound of claim 1 wherein Y is an unsubstituted alkylene of 1-3 carbons, —C(═O)—, —CH2O—, —S—, —O—, or —CH═CH—.

### Claim 8 (depends on 1)

The compound of claim 1 having formula:
32

### Claim 9 (depends on 8)

The compound of claim 8 wherein rings B and F are phenyl.

### Claim 10 (depends on 9)

The compound of claim 9 wherein R1, R3, and R5 are H.

### Claim 11 (depends on 9)

The compound of claim 9 wherein A1 and A2 are selected from H, H; H, OH; H, —OCH3; H, —N(R12)2; or a group where A1 and A2 together form ═O or ═NR12; B1 and B2 are selected from H, H; H, OH; H, —OCH3; H, —N(R12)2; or a group where B1 and B2 together form ═O or ═NR12; and R12 is H, methyl, ethyl, propyl, —OH, or methoxy.

### Claim 12 (depends on 9)

The compound of claim 9 wherein R6 is H or substituted or unsubstituted lower alkyl.

### Claim 13 (depends on 9)

The compound of claim 9 wherein Y is an unsubstituted alkylene of 1-3 carbons, —C(═O)—, —CH2O—, —S—, —O—, or —CH═CH—.

### Claim 14 (depends on 1)

The compound of claim 1 having the formula:
33 34 35 36 37 38 39 40 41 42 43 44 45

### Claim 15 (depends on 1, 2)

A pharmaceutical composition comprising a compound of claim 1 or claim 2 and a pharmaceutically acceptable carrier.

### Claim 16 (depends on 14)

A pharmaceutical composition comprising a compound of claim 14 and a pharmaceutically acceptable carrier.

### Claim 17 (depends on 1, 2)

A pharmaceutical composition for treating or preventing prostate disorders comprising a compound of claim 1 or claim 2 and a pharmaceutically acceptable carrier.

### Claim 18 (depends on 17)

The pharmaceutical composition of claim 17 wherein the prostate disorder is prostate cancer or benign prostate hyperplasia

### Claim 19 (depends on 1, 2)

A pharmaceutical composition for treating or preventing angiogenic disorders comprising a compound of claim 1 or claim 2 and a pharmaceutically acceptable carrier.

### Claim 20 (depends on 19)

The pharmaceutical composition of claim 19 wherein the angiogenic disorder is cancer of solid tumors, endometriosis, diabetic retinopathy, psoriasis, hemangioblastoma, ocular disorders or macular degeneration.

### Claim 21 (depends on 1, 2)

A pharmaceutical composition for treating or preventing neoplasia, rheumatoid arthritis, pulmonary fibrosis, myelofibrosis, abnormal wound healing, atherosclerosis, or restenosis comprising a compound of claim 1 or claim 2 and a pharmaceutically acceptable carrier.

### Claim 22 (depends on 1, 2)

A pharmaceutical composition for treating or preventing Atzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, stroke, ischaemia, Huntington's disease, AIDS dementia, epilepsy, multiple sclerosis, peripheral neuropathy, or injuries of the brain or spinal chord comprising a compound of claim 1 or claim 2 and a pharmaceutically acceptable carrier.

### Claim 23 (depends on 1, 2)

A method for inhibiting trk kinase activity comprising providing a compound of claim 1 or claim 2 in an amount sufficient to result in effective inhibition.

### Claim 24 (depends on 23)

The method of claim 23 wherein the trk kinase is trk A.

### Claim 25 (depends on 1, 2, 23)

The method of claim 23 wherein the compound of claim 1 or claim 2 is provided to treat inflammation.

### Claim 26 (depends on 1, 2)

A method for treating or preventing prostate disorders which comprises administering to a host in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1 or claim 2.

### Claim 27 (depends on 26)

The method of claim 26 wherein the prostate disorder is prostate cancer or benign prostate hyperplasia.

### Claim 28 (depends on 1, 2)

A method for treating or preventing angiogenic disorders which comprises administering to a host in need of such treatment or prevention a therapeutic effective amount of a compound of claim 1 or claim 2.

### Claim 29 (depends on 28)

The method of claim 28 wherein the angiogenic disorder is cancer of solid tumors, endometriosis, diabetic retinopathy, psoriasis, hemangioblastoma, ocular disorders or macular degeneration.

### Claim 30 (depends on 1, 2)

A method for treating or preventing disorders where PDGFR activity contributes to pathological conditions comprising providing a compound of claim 1 or claim 2 in an amount sufficient to result in the platelet derived growth factor receptor being contacted with an effective inhibitory amount of the compound.

### Claim 31 (depends on 1, 2)

A method for treating or preventing neoplasia, rheumatoid arthritis, pulmonary fibrosis, myelofibrosis, abnormal wound healing, atherosclerosis, or restenosis which comprises administering to a host in need of such treatment or prevention a therapeutic effective amount of a compound of claim 1 or claim 2.

### Claim 32 (depends on 1, 2)

A method for treating or preventing disorders characterized by the aberrant activity of trophic factor responsive cells comprising providing a compound of claim 1 or claim 2 in an amount sufficient to result in the trophic factor cell receptor being-contacted with an effective activity inducing amount of the compound.

### Claim 33 (depends on 1, 2)

A method for treating or preventing Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, stroke, ischaemia, huntington's disease, AIDS dementia, epilepsy, multiple sclerosis, peripheral neuropathy, or injuries of the brain or spinal chord comprising administering to a host in need of such treatment or prevention a therapeutic effective amount of a compound of claim 1 or claim 2.
